ABSTRACT Background: Previous data support the benefits of reducing dietary saturated fatty acids (SFAs) on insulin resistance (IR) and other metabolic risk factors. However, whether the IR status of those suffering from metabolic syndrome (MetS) affects this response is not established. Objective: Our objective was to determine whether the degree of IR influences the effect of substituting high-saturated fatty acid (HSFA) diets by isoenergetic alterations in the quality and quantity of dietary fat on MetS risk factors. Design: In this single-blind, parallel, controlled, dietary intervention study, MetS subjects (n = 472) from 8 European countries classified by different IR levels according to homeostasis model assessment of insulin resistance (HOMA-IR) were randomly assigned to 4 diets: an HSFA diet; a high-monounsaturated fatty acid (HMUFA) diet; a low-fat, high-complex carbohydrate (LFHCC) diet supplemented with long-chain n-3 polyunsaturated fatty acids (1.2 g/d); or an LFHCC diet supplemented with placebo for 12 wk (control). Anthropometric, lipid, inflammatory, and IR markers were determined. Results: Insulin-resistant MetS subjects with the highest HOMA-IR improved IR, with reduced insulin and HOMA-IR concentrations after consumption of the HMUFA and LFHCC n-3 diets (P , 0.05). In contrast, subjects with lower HOMA-IR showed reduced body mass index and waist circumference after consumption of the LFHCC control and LFHCC n-3 diets and increased HDL cholesterol concentrations after consumption of the HMUFA and HSFA diets (P , 0.05). MetS subjects with a low to medium HOMA-IR exhibited reduced blood pressure, triglyceride, and LDL cholesterol levels after the LFHCC n-3 diet and increased apolipoprotein A-I concentrations after consumption of the HMUFA and HSFA diets (all P , 0.05). Conclusions: Insulin-resistant MetS subjects with more metabolic complications responded differently to dietary fat modification, being more susceptible to a health effect from the substitution of SFAs in the HMUFA and LFHCC n-3 diets. Conversely, MetS subjects without IR may be more sensitive to the detrimental effects of HSFA intake. The metabolic phenotype of subjects clearly determines response to the quantity and quality of dietary fat on MetS risk factors, which suggests that targeted and personalized dietary therapies may be of value for its different metabolic features. This study was registered at clinicaltrials.gov as NCT00429195.
Lifestyle behaviors, including diet and physical activity, may be more effective in preventing the development of MetS than pharmacologic agents (7) . Although diet is not identified as a risk factor for MetS, intervention studies have consistently shown inverse associations between whole grain, fruit, and vegetable intake, as well as Mediterranean-type diets (which are rich in MUFAs), and MetS risk (8, 9) , whereas high-fat diets and particularly those rich in SFAs may increase serum triglycerides, reduce HDL, and promote obesity, inflammation, IR, and MetS (10) (11) (12) (13) (14) . Notwithstanding this evidence, it has also been demonstrated that very-low-carbohydrate, very-high-fat interventions designed to promote ketogenesis also improve the risk factors of T2DM (15, 16) . Intake of long-chain n-3 PUFAs in intervention studies has failed to show a consistent effect on IR in subjects with MetS (17) (18) (19) . However, most of these studies showed an improvement in some obesity-associated MetS features, such as hypertension and dyslipidemia, by decreasing plasma triglycerides (20, 21) .
Although previous data support the benefits of dietary fat modification on MetS, it is difficult to define the optimal diet with which to treat and prevent MetS from a clinical perspective. Moreover, it is unclear whether the presence of IR, as one of the major contributors to the development of MetS, may influence this response. On the other hand, HOMA-IR has proved to be a robust tool for the surrogate assessment of IR (22, 23) , although there is great variability in threshold HOMA-IR concentrations to define and establish IR accurately (24, 25) .
Thus, our objective was to determine whether HOMA-IR influences the effect of substituting high-SFA diets by isoenergetic alterations in the quality and quantity of dietary fat on MetS risk factors (NCT00429195). This is a post hoc analysis of the large LIPGENE dietary intervention study, the main outcomes of which were already reported (17) .
METHODS

Participants and recruitment
The LIPGENE human dietary intervention study was a randomized controlled trial that complied with the 1983 Helsinki Declarations and was approved by the local ethics committees of the 8 intervention centers (Dublin, Ireland; Reading, United Kingdom; Oslo, Norway; Marseille, France; Maastricht, Netherlands; Córdoba, Spain; Krakow, Poland; and Uppsala, Sweden). Written informed consent was obtained from every participant and approved by each institutional ethical committee. The eligibility of participants, who were aged 35-70 y with a BMI (in kg/m 2 ) of 20-40, was determined with the use of a modified version of the National Cholesterol Education Program criteria for MetS (26) . Participants were characterized by at least 3 of the following 5 criteria: waist circumference (WC) .102 cm (men) or .88 cm (women); fasting plasma glucose concentration 5.5-7.0 mmol/L; triglycerides $1.5 mmol/L; HDL cholesterol ,1.0 mmol/L (men) or ,1.3 mmol/L (women); and blood pressure $130/85 mm Hg or treatment for previously diagnosed hypertension. Detailed characteristics of this cohort have been published (8, 27) .
Anthropometric measurements were recorded according to a standardized protocol for the LIPGENE study and blood pressure was measured according to the European Society of Hypertension guidelines (28) . Of a potential 535 eligible volunteers, 486 entered the study and completed most of the preintervention clinical investigation, such as the intravenous glucose tolerance test and anthropometric and dietary assessments. The present analyses include pre-and postintervention data for 472 subjects who completed the dietary intervention, who were divided in the following tertiles according to different cutoffs for HOMA-IR: tertile 1 (low HOMA-IR): ,1.90; tertile 2 (medium HOMA-IR): 1.90-2.93; and tertile 3 (high HOMA-IR): .2.93. HOMA-IR was not available in 14 of these volunteers; therefore, analysis was completed in 486 2 14 = 472 subjects.
Random assignment and dietary intervention
Random assignment and intervention have been previously described (27) . Briefly, random assignment was completed according to age, sex, and fasting plasma glucose concentration. Each subject was randomly stratified to one of 4 dietary interventions for 12 wk. The diets differed in fat quantity and quality while remaining isoenergetic, excluding the effects of weight change.
The composition of the 4 diets was as follows:
The HSFA diet was the reference diet and reflected the traditional fat content and composition of typical Northern European diets (27) . The intervention diets were specifically designed to reduce dietary SFAs by replacement with MUFAs or as part of an LFHCC diet, while keeping dietary energy and n-6 PUFAs unaltered.
Dietary assessment
A common training protocol and standard operating procedures were developed to standardize collection of biological samples and dietary data in each center. A 3-d weighted food dietary record (2 weekdays and 1 weekend day) assessed preintervention habitual dietary intake and was used to design individualized isoenergetic dietary fat modification (29) . Two weighted 3-d food dietary records were completed mid-and postintervention at weeks 6 and 12 of the intervention period to assess compliance (27) . Physical activity, alcohol consumption, and smoking habits were unaltered. Compliance was assessed by dietary assessment, capsule count, and plasma fatty acid pattern analysis.
Biochemical measurements
Participants arrived at the clinic center at 0800 after a 12-h fast, refrained from smoking during the fasting period, and abstained from alcohol intake during the preceding 7 d. In the laboratory and after cannulation, fasting blood was taken before and after intervention (at the end of intervention), as previously described (30) . Total cholesterol and triglycerides were quantified with the use of an IL Test Triglycerides kit (Instrumentation Laboratory). An IL Test HDL cholesterol kit (Instrumentation Laboratory) was used for direct quantification of HDL cholesterol. LDL-cholesterol concentrations were estimated with the use of the Friedewald formula based on total cholesterol, triglyceride, and HDL-cholesterol concentrations. Plasma concentrations of adiponectin, leptin, soluble vascular cellular adhesion molecule 1 (VCAM-1), soluble intercellular adhesion molecule 1 (ICAM-1), IL-6, and TNF-a were measured by ELISA (DuoSet ELISA Development System DY1065, DY398, DY809, DY720, DY206 and DY210; R&D Systems).
Plasma glucose concentrations were measured with the use of an IL Test Glucose Hexokinase Clinical Chemistry kit (Instrumentation Laboratory). Plasma insulin concentrations were measured by solid-phase, 2-site fluoroimmunometric assay on a 1235 automatic immunoassay system (Auto-DELFIA kits, Wallac Oy).
HOMA-IR was derived from fasting insulin (microunits per liter) 3 fasting glucose (micromoles per liter)/22.5. An insulinmodified intravenous glucose tolerance test was performed (31) . Measures of insulin sensitivity [insulin sensitivity index (ISI)] were determined with the use of the MINMOD Millenium Program (version 6.02, Richard N Bergman). The acute insulin response to glucose (AIRg) (first-phase insulin response) was defined as the incremental AUC from time 0-8 min. Disposition index (DI) was calculated as the product of AIRg and ISI.
Statistical analysis
Biochemical variables were assessed for normal distribution, and skewed variables were normalized by log10 or square-root transformation as appropriate. Statistical analyses were carried out with the use of SPSS version 18.0 for Windows. HOMA-IR was analyzed as tertiles after removal of experimental outliers. HOMA-IR was categorized into tertiles (smallest to highest) and analyzed as a categorical variable. This resulted in the following distribution of HOMA-IR: tertile1-HOMA-IR ,1.90; tertile 2-HOMA-IR 1.90-2.93; and tertile 3-HOMA-IR .2.93. An independent-samples t test, repeated-measures ANOVA, and univariate ANOVA were used where appropriate. Bonferroni's test was used when post hoc analysis was required. Differences were considered to be significant when P , 0.05. All data are means 6 SDs.
RESULTS
Baseline characteristics
The clinical characteristics of MetS subjects according HOMA-IR tertiles are presented in Table 1 . Systolic blood pressure (SBP), diastolic blood pressure (DBP), and plasma triglyceride concentrations were higher in the MetS subjects with greater HOMA-IR (tertiles 2 and 3) than in those with the lowest HOMA-IR (P , 0.05). Weight, BMI, WC, fasting glucose, fasting insulin, AIRg, leptin, VCAM-1, and ICAM-1 concentrations were higher, and ISI, DI, HDL cholesterol, and adiponectin concentrations were lower in the MetS subjects with the highest HOMA-IR (tertile 3) than in those with medium or low HOMA-IRs (tertiles 1 and 2) (P , 0.05). Subjects grouped in tertile 2 for HOMA-IR presented an intermediate effect in weight, BMI, WC, fasting glucose, insulin, and ISI compared with low HOMA-IR MetS subjects (tertile 1) (P , 0.05).
Efficacy of dietary fat intervention on markers of IR determined by degree of IR
The effects of dietary fat interventions (changes between preand postintervention) on markers related to both insulin sensitivity and secretion are presented in Table 2 . Fasting insulin and HOMA-IR concentrations decreased after consumption of the HMUFA and LFHCC n-3 diets in the most insulin-resistant group (tertile 3) (HOMA-IR .2.93), and these decreases in the 2 markers were significantly lower than with the HSFA diet (P , 0.05). Interestingly, the dietary fat modification-induced changes in IR with the HMUFA diet were not linked to weight loss, BMI, and WC. In contrast, the least insulin-resistant group (tertile 1) was most sensitive to the HSFA diet, in which fasting insulin and HOMA-IR concentrations increased after consumption of the HSFA diet (P = 0.027 and 0.005, respectively). Moreover, these increases were significant compared with the HMUFA and LFHCC n-3 diets (Table 2 ). Dietary fat modification did not affect other markers of insulin sensitivity, including fasting glucose concentrations, ISI, AIRg, and DI. BMI and WC were reduced after consumption of the LFHCC control and LFHCC n-3 diets in the MetS subjects with low HOMA-IR (tertiles 1 and 2).
Differential effect of dietary intake determined by the degree of IR on anthropometric and lipid markers and blood pressure
The effects of dietary fat interventions (changes produced comparing pre-and postintervention) on anthropometric measurements, lipid markers, and blood pressure are presented in Table 3 . BMI decreased in the MetS subjects with lower HOMA-IR (tertiles 1 and 2), and WC was reduced in tertile 1 after consumption of the LFHCC control and LFHCC n-3 diets compared with the HSFA and HMUFA diets (all P , 0.05). DBP, SBP, and LDL-cholesterol concentrations decreased after consumption of the LFHCC n-3 diet; these decreases were significant after consumption of this diet compared with the other diets only in subjects with the lowest HOMA-IR (all P , 0.05).
HDL-cholesterol concentrations increased after consumption of the HMUFA and HSFA diets in MetS subjects grouped in tertiles 1 and 2 in comparison with the other diets (all P , 0.05). Apolipoprotein A-I concentrations also increased in subjects with the lowest HOMA-IR after consumption of the HMUFA and HSFA diets (P = 0.007 and 0.021, respectively) compared with the LFHCC control and LFHCC n-3 diets (P , 0.05). The LFHCC n-3 diet reduced triglyceride concentrations in the MetS subjects grouped in tertiles 1 and 2 compared with the other diets (P = 0.019 and 0.015, respectively) ( Table 3 ). In contrast, the hypotriglyceridemic potential of long-chain n-3 PUFAs was not demonstrated in subjects with the highest HOMA-IR (tertile 3).
Differential effect of dietary intake determined by the degree of IR on cytokines and adipokines
In MetS subjects with a lower HOMA-IR (tertiles 1 and 2), plasma IL-6 concentrations were reduced after consumption of the HMUFA and LFHCC n-3 diets, compared with the HSFA and LFHCC control diets (all P , 0.05). (Table 4) . However, IL-6 was not modified by these diets in individuals with a high HOMA-IR. Adiponectin, leptin, TNF-a, VCAM-1, and ICAM-1 concentrations were unaffected by the degree of IR after consumption of the different diets (Table 4) .
DISCUSSION
The aim of the current study was to determine whether the degree of IR affects the response to isoenergetic dietary fat interventions to reduce the risk factors of MetS. The intervention involved the reduction of dietary SFA intake by substitution with MUFAs or as part of an LFHCC diet, with or without supplementation with long-chain n-3 PUFAs. Indeed, in our initial analysis without stratifying the LIPGENE population into tertiles according to HOMA-IR, (17) , there was no significant effect on IR from reducing SFAs. However, it needs to be acknowledged that response to dietary intervention has a significant between-person variation. The degree of IR is an important issue in terms of defining potential responsiveness to lifestyle modifications and, thus, developing a better understanding of personalized health. Interestingly, these MetS subjects, who were classified by different HOMA-IR cutoffs, showed a differential response to dietary SFA substitution. The removal of dietary SFAs attenuated IR in those MetS subjects with the greatest HOMA-IR (.2.93), who showed a decrease in fasting insulin concentrations and HOMA-IR when they consumed the HMUFA and LFHCC n-3 diets, compared with those who consumed the HSFA diet. However, markers related to insulin sensitivity and secretion, such as ISI, AIRg, DI, or fasting glucose, were unaltered in the 3 subgroups of MetS subjects. Different studies have attempted to assess the relation between HOMA-IR and ISI and have found discrepancies (32, 33) , as occur in our results. A feasible explanation for that could be that HOMA-IR is a fasting index, as well as a measure of IR, whereas ISI is a dynamic index that measures insulin sensitivity. The advantage of indexes based on dynamic testing is that information about insulin secretion can be obtained at the same time as information about insulin action. However, if one is interested only in estimating insulin sensitivity/ resistance, fasting surrogates may be preferable to dynamic surrogates because they are simpler to obtain (34, 35) . On the other hand, MetS subjects with the lowest HOMA-IR (,1.90) exhibited an improvement in several MetS risk factors, including a decrease in BMI after consumption of the LFHCC control and LFHCC n-3 diets compared with the HSFA and HMUFA diets, a reduction in blood pressure (both DBP and SBP), a reduction in LDL cholesterol and triglyceride concentrations after consumption of the LFHCC n-3 diet compared with the other diets, and an increase in HDL cholesterol and apolipoprotein A-I concentrations after consumption of the HSFA and HMUFA diets compared with the LFHCC control and LFHCC n-3 diets. Moreover, IL-6 was the only variable related to inflammation that responded to dietary fat modification. Plasma IL-6 concentrations were only reduced after consumption of the HMUFA and LFHCC n-3 diets in MetS subjects with low and medium HOMA-IR concentrations compared with the other diets (,1.90 and 1.90-2.93, respectively). Cross-sectional, intervention, and experimental data suggest that high-fat diets promote obesity, IR, and inflammation, driving the development of MetS, T2DM, and cardiovascular disease (36, 37) . However, there is a large and increasing body of published evidence from other human studies that shows no clear effects from SFA consumption on vascular function, IR, diabetes, and stroke, highlighting a need for further investigation of these endpoints (38) (39) (40) . Conversely, different dietary intervention studies have analyzed the effect of changes in dietary fat on insulin sensitivity and secretion. The KANWU study found an improvement in insulin sensitivity, but not in insulin secretion, in healthy subjects when dietary SFAs were substituted by MUFAs (41) . Other authors have suggested a beneficial effect from MUFA diets compared with SFA and high-carbohydrate diets on insulin sensitivity and glycemic response in MetS subjects (42, 43) . However, the effects of n-3 PUFAs on insulin sensitivity and secretion are controversial, showing a neutral/ marginal effect in related indexes in healthy subjects (41) and in both insulin-resistant and T2DM subjects (44) .
The addition of n-3 fatty acids influenced neither insulin sensitivity nor insulin secretion.
In this sense, our results demonstrated that consumption of both the HMUFA and LFHCC n-3 diets reduced fasting insulin concentrations and HOMA-IR, but consumption of other diets did not; this occurred only in those MetS patients with the greatest HOMA-IR, although the other variables related to insulin sensitivity were not affected. On the other hand, consumption of an HSFA diet produced an increase in fasting insulin and HOMA-IR in MetS subjects with lower HOMA-IR. Similarly, and in agreement with most dietary fat modification 93 ). *Significant changes between Post and Pre in each diet (P , 0.05). Means in a row without a common superscript letter differ significantly, P , 0.05. Apo, apolipoprotein; DBP, diastolic blood pressure; HMUFA, high MUFA; HSFA, high SFA; LFHCC, low fat, high complex carbohydrate; Post, postintervention; Pre, preintervention; SBP, systolic blood pressure; WC, waist circumference. studies, we did not find an effect from reducing dietary SFAs on insulin secretion in any MetS subject groups.
Interestingly, we observed that the LFHCC n-3 diet significantly reduced both SBP and DBP in MetS subjects with lower HOMA-IR. Similarly, the hypotensive effect of the LFHCC n-3 diet was also demonstrated in our MetS population (45) . In contrast, other studies that compared high-carbohydrate with high-MUFA diets observed no differences in the blood pressure response, or were even favorable to MUFA diets (46) . However, an independent inverse relation of total n-3 PUFA intake to SBP and DBP has been shown in a population-based study on food n-3 PUFA intake (47) .
It has been well described that the potential hypertriglyceridemic effect of an LFHCC diet could be ameliorated by long-chain n-3 PUFA supplementation (20) . Although we previously reported that an LFHCC n-3 diet reduced plasma triglyceride concentrations in MetS subjects, this effect was most striking in men (17) . In the current analysis, we demonstrated that long-chain n-3 PUFAs only effectively reduced plasma triglyceride concentrations, in association with reduced LDL cholesterol concentrations in MetS subjects with a low to medium HOMA-IR.
HDL is a major risk factor for coronary artery disease and its reduction is a very important risk factor for MetS. In our study, HDL cholesterol concentrations were increased after the 2 highfat diets (HSFA and HMUFA), reflecting the well-characterized impact of total fat on HDL metabolism. When specific types of fatty acids were analyzed, SFA and MUFA intake, but not for PUFA intake, were associated with higher HDL cholesterol content (48) . However, this increase in HDL cholesterol concentrations only occurred in MetS subjects with lower HOMA-IR, which is in agreement with other intervention studies (41, 49) .
In the full cohort, the LIPGENE intervention study showed no significant effect from dietary fat modification on several markers of inflammation, coagulation, lipid peroxidation, and oxidative stress (50) . Interestingly we observed that the HMUFA and LFHCC n-3 diets significantly reduced plasma IL-6 concentrations in MetS subjects with low-medium HOMA-IR. In contrast, these diets had no impact on IL-6 in the subjects with the greatest IR. It is difficult to modify the inflammatory phenotype of dietary fat modification alone in weight-stable MetS individuals, particularly considering a situation of IR. A related study showed that long-chain n-3 PUFA supplementation reduced plasminogen activator inhibitor-1 concentrations, but not leptin, adiponectin, IL-6, or TNF-a concentrations (19) . However, there are several other studies that have shown little effect.
Despite the evidence, we should be cautious in the interpretation of our results. The LIPGENE cohort is a very-wellcharacterized population, and the multicenter origin of the subjects allows extrapolation of the results to the European population. A limitation is ensuring complete adherence to dietary instructions in a feeding trial. However, adherence to recommended dietary patterns was good, as judged by dietary assessment. Also, we have to point out that our study represents a secondary analysis of the LIPGENE study. More studies would be required specifically designed for this purpose.
In summary, MetS is a heterogeneous condition requiring targeted and personalized dietary therapies for its different metabolic features. Our data support earlier findings, from a cross-sectional study, that reported a differential response to modifications in dietary fat in MetS subjects divided according to different HOMA-IR cutoffs. We could suggest that those MetS subjects with IR (greater HOMA-IR) showed more metabolic complications and may be more susceptible to the healthy effects of dietary SFA substitution, which favors the HMUFA and LFHCC n-3 diets. However, although MetS subjects without IR (lower HOMA-IR) showed improvement in other metabolic risk factors related to MetS, such as obesity, blood pressure, and lipid markers, mainly after consumption of the LFHCC n-3 diet, they may be more responsive to the detrimental effects of the HSFA diet.
However, a confirmation of this hypothesis would require a study designed specifically to address this issue. More extensive dietary fat modification studies are needed to extend the knowledge about the quantity and quality of dietary fat on MetS risk factors and to shed more light on nutrition based on therapeutic strategies for IR on metabolic syndrome.
